Tech Company Financing Transactions
CytoMed Therapeutics Funding Round
ICH Capital participated in a capital raise for CytoMed Therapeutics. The round was announced on 11/6/2025.
Transaction Overview
Company Name
Announced On
11/6/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
ICH Capital (Vincent Toe)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Singapore, Undisclosed
Singapore
Singapore, Undisclosed
Singapore
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
CHOO Kong
Browse more venture capital transactions:
Prev: 11/6/2025: Motley venture capital transaction
Next: 11/6/2025: Synchron venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs